Most-favoured-nation designs are often framed in Washington as a domestic rebate tool. For leaders who own value, pricing and access, that view is too narrow. Fresh modelling of mandatory Medicare payment models shows that MFN pricing dynamics operate as a global feedback loop. The scale of modelled United States savings relative to sales in the cheapest reference country is large enough to alter launch timing, public list architecture and the practical worth of international benchmarks for European, and other high-income payers. This reflection sets out what those ratios imply for health economics, reimbursement strategy and system dynamics once manufacturers and reference countries begin to adapt.

Strategic Signals Hidden in the Ratios

The Centers for Medicare and Medicaid Services has outlined mandatory most-favoured-nation models for brand-name medicines in Medicare Part B (GLOBE) and Part D (GUARD). Manufacturers would pay extra rebates when net US prices exceed the lowest international list price in a basket of 19 reference countries, adjusted by GDP per capita on a purchasing-power-parity basis. The basket spans Australia, Canada, Japan, South Korea, Israel, the United Kingdom, Switzerland and a broad European set. Hwang and colleagues linked Medicare spending to rebate estimates and international sales for 195 branded products that together represent 87.9 billion US dollars of Medicare expenditure.

Modelled net-spend reductions reach 5.2 billion dollars (16.1 per cent) under GLOBE and 6.4 billion dollars (17.6 per cent) under GUARD. Those headline figures will dominate American debate. The access-relevant finding lies one layer deeper. The median ratio of estimated Medicare savings to annual sales in the binding lowest-priced country is 3.8. For 101 of 138 products with a clear binding country (73.2 per cent), the US reduction would exceed that country’s entire annual sales of the same medicine. That ratio is the strategic fact. A company that accepts the lowest public list in a small high-income market as a visible anchor is no longer making a purely local decision; it is placing a multiple of that market’s revenue at risk in the United States.

Design Details That Shift Corporate Calculus

Two features of the design deserve sharper attention than early coverage has given them. After GDP-PPP adjustment the binding country is frequently not Germany or France. South Korea, Norway and Australia set the largest shares of the modelled anchors. Launch sequencing and list-price architecture in mid-sized high-income markets now carry US revenue consequences that many European affiliates have never been asked to price into their plans. Equally material, modelled US saving collapses by more than two-thirds if manufacturers holding separate confidential agreements with the administration are exempted. Scope, not only the formula, will determine how much behavioural pressure actually transmits abroad.

Health Economics and the Weakening of Observable Prices

Health economics teams will encounter the study first as a data problem. International reference pricing and analogue-based corridors already rest on public lists that poorly describe net transaction prices. If manufacturers respond by inflating lists and deepening confidential discounts, the observed international price becomes a weaker input to both value-based pricing corridors and budget impact models. The uncertainty is structural: the list that HTA and pricing teams can see is the list companies now have an incentive to manage.

Value assessment methods themselves do not change because of a US rebate rule. What changes is the evidence calendar. Delayed launch in a reference country postpones local utilisation data, local costing and the real-world comparators that national bodies still require after a Joint Clinical Assessment. Cost-effectiveness models built on early European uptake assumptions will need explicit launch-timing scenarios rather than a single expected date. Budget impact projections that treat first-year volume as a simple function of epidemiology and share of voice will understate the risk that the product is simply not offered, or is offered late, in the markets that set the US floor. External evidence and managed-entry designs therefore become more, not less, important. Coverage with evidence development, outcome-linked contracts and staged indication expansion remain the practical instruments for turning a delayed or thin local evidence base into a structured data plan.

Pricing Strategies and Reimbursement Decisions Under Interdependence

Pricing strategies can no longer be organised as a sequence of national negotiations that happen to be observed elsewhere. The reported ratios make launch order itself a pricing instrument. A first sale in a low-list basket country is a potential US rebate event. That does not mean every European or Asia-Pacific launch should be postponed. It does mean that the first-wave country set, the published list, the presentation and pack, and the confidentiality of the net price must be designed as one file.

Reimbursement decisions face the mirror problem. If companies raise public lists to protect the US book, headline prices in Europe and other reference markets will look less affordable even when net prices remain stable. Political and media attention will attach to the list. Payers who rely on international reference pricing as a primary lever will find that the lever now moves in two directions: Washington uses it to pull US prices down, while manufacturers can use it to push foreign lists up or keep them from forming. Confidential net pricing, already the working currency of many European negotiations, becomes both more valuable and more contested. Directors should treat the underlying mechanism as a planning assumption and demand asset-level scenarios rather than wait for cleaner causal proof of any single delayed launch.

System Dynamics and Policy Implications

The useful reading of the work is as a description of coupled markets. A rebate rule in Medicare changes the payoff to a visible price in Korea, Norway or Australia. That change alters launch timing in those countries. Delayed or missing prices then feed back into US savings, European IRP baskets, Joint Clinical Assessment-to-national pricing hand-offs, and the political claim that Europe free-rides on American innovation. Each actor responds locally; the system result is a different access path.

Three loops matter for policy implications. The launch-delay loop protects the US book by withholding a low public list, at the cost of later access for patients in the binding country and in any market that waits on that first price. The list-versus-net loop protects the US book by publishing a higher list and hiding the concession, at the cost of transparency for every payer that still references lists. The exemption loop allows bilateral agreements to shrink the mandatory model, reduce modelled US savings and redistribute pressure onto companies that remain inside the formula. Reference countries have limited fiscal room simply to raise budgets so that their lists no longer bind. European and other high-income systems that want predictable access must therefore decide whether they will defend confidential nets more firmly, accept later launches, or redesign how they publish and reference prices.

Closing Perspective for Senior Decision-Makers

The study does not settle whether most-favoured-nation pricing is sound US policy. It does settle a narrower and more useful question for access leaders. When the US saving on a product is several times the annual sales in the country that sets the reference, manufacturer behaviour in that country becomes part of the US model, and US rules become part of every other country’s access path. MFN pricing dynamics therefore require decision-makers to treat launch order, public lists and confidential nets as connected variables. Those who do so will be better placed to protect both revenue and timely patient access. Those who continue to price each market as if the others were only watching will discover that the others are already inside the equation.

Frequently Asked Questions

How do MFN pricing dynamics affect launch timing in smaller reference markets?

When modelled US savings greatly exceed a reference country’s annual sales, companies often delay or restructure launches there to avoid triggering large Medicare rebates, which can push first-wave pricing decisions into a single global file rather than isolated national negotiations.

Will confidential discounts become more common because of these dynamics?

Yes. Manufacturers have an incentive to raise public lists while deepening hidden rebates, which weakens the reliability of observable prices for international reference pricing and forces HTA bodies to rely more on managed-entry agreements and outcome-linked contracts.

Do MFN pricing dynamics change how health economists should build budget-impact models?

They should add explicit MFN-exposure scenarios that test delayed launch years, altered list prices in binding countries, and slower uptake in markets waiting on the first OECD price, reporting ranges instead of single-point estimates.

This reflection draws on the editorial published in Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01555-2/fulltext)